Fig. 4: Using Molecular Group to predict response to adjuvant RT in meningiomas after surgery.

a, PFS of cases in the retrospective molecular meningioma cohort that received adjuvant RT after surgery stratified by Molecular Group. b, Covariate balance before PSM (unadjusted) and after PSM (adjusted) for meningiomas treated with adjuvant RT (+RT) versus observation (Obs) after surgery. c, Above, PFS of the PSM retrospective cohort comparing meningiomas that received adjuvant RT (+RT) after surgery to those that were observed (Obs) in each respective Molecular Group; below, the proportion of these matched cases that received GTR and STR in each Molecular Group. d,e, Molecular cohort of RTOG-0539 clinical trial cases used as a validation cohort here, including their originally defined risk groups and their reclassification into Molecular Groups after molecular profiling. f, Genome-wide chromosomal arm-level copy number alterations called based on DNA methylation of molecularly profiled RTOG-0539 cases organized by Molecular Group. g, PFS of meningiomas from the RTOG-0539 trial that received adjuvant RT after surgery (defined as the original ‘intermediate-risk’ and ‘high-risk’ treatment arms of the trial) stratified based on Molecular Group. h, Schematic of separate PSM analysis mimicking a randomized controlled trial with the RT arm composed entirely of RT-treated meningiomas from the prospective RTOG-0539 cohort and the control/observation arm composed of retrospective meningioma cases that did not receive adjuvant RT after surgery. i, Covariate balance before and after the PSM schema outlined in k. j, PFS analysis of PSM meningioma cohort stratified based on receipt of adjuvant RT (+RT; comprising only cases from the RTOG-0539 trial) versus observation (Obs; non-RTOG-0539 cases only) in each Molecular Group.